Literature DB >> 28509433

Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force.

Frank M Balis1, Richard B Womer1, Stacey Berg2, Naomi Winick3, Peter C Adamson1, Elizabeth Fox1.   

Abstract

An analysis of dose modifications for infants in 29 Children's Oncology Group protocols across 10 cancer types revealed 11 sets of criteria defining the infant population using age, weight, body surface area (BSA), or a combination of these parameters and eight dose modification methods. A new method of dosing anticancer drugs in infants was developed based on the rationale that prior modifications were implemented to reduce toxicity, which is not cancer-specific. The new method uses BSA dose banding in dosing tables for infants and children with a BSA <0.6 m2 and gradually transitions from body weight based to BSA-based dosing.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  anticancer drugs; body surface area; dose; infants

Mesh:

Substances:

Year:  2017        PMID: 28509433     DOI: 10.1002/pbc.26636

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

1.  Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.

Authors:  Erin M Guest; Richard Aplenc; Lillian Sung; Susana C Raimondi; Betsy A Hirsch; Todd A Alonzo; Robert B Gerbing; Yi-Cheng Jim Wang; Samir B Kahwash; Amy Heerema-McKenney; Soheil Meshinchi; Alan S Gamis
Journal:  Blood       Date:  2017-07-03       Impact factor: 22.113

2.  Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1.

Authors:  Jeffrey Skolnik; David Hall; Donald A Barkauskas; Ganesh Moorthy; Thomas R Larson; Elizabeth Fox; Brenda J Weigel; Stacey L Berg; Joel M Reid
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-22       Impact factor: 3.288

Review 3.  Therapeutic Drug Monitoring Is a Feasible Tool to Personalize Drug Administration in Neonates Using New Techniques: An Overview on the Pharmacokinetics and Pharmacodynamics in Neonatal Age.

Authors:  Domenico Umberto De Rose; Sara Cairoli; Marco Dionisi; Alessandra Santisi; Luca Massenzi; Bianca Maria Goffredo; Carlo Dionisi-Vici; Andrea Dotta; Cinzia Auriti
Journal:  Int J Mol Sci       Date:  2020-08-17       Impact factor: 5.923

4.  Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations.

Authors:  Shelby Barnett; Victoria Holden; Quentin Campbell-Hewson; Gareth J Veal
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

Review 5.  Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance.

Authors:  A Laura Nijstad; Shelby Barnett; Arief Lalmohamed; Inez M Bérénos; Elizabeth Parke; Vickyanne Carruthers; Deborah A Tweddle; Jordon Kong; C Michel Zwaan; Alwin D R Huitema; Gareth J Veal
Journal:  Eur J Cancer       Date:  2021-12-02       Impact factor: 9.162

6.  Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients.

Authors:  Shelby Barnett; Farina Hellmann; Elizabeth Parke; Guy Makin; Deborah A Tweddle; Caroline Osborne; Georg Hempel; Gareth J Veal
Journal:  Eur J Cancer       Date:  2021-10-14       Impact factor: 9.162

7.  Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.

Authors:  Melanie White-Koning; Caroline Osborne; Angelo Paci; Alan V Boddy; Etienne Chatelut; Gareth J Veal
Journal:  Eur J Cancer       Date:  2018-01-12       Impact factor: 9.162

8.  Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.

Authors:  Christian Siebel; Gudrun Würthwein; Claudia Lanvers-Kaminsky; Nicolas André; Frank Berthold; Ilaria Castelli; Pascal Chastagner; François Doz; Martin English; Gabriele Escherich; Michael C Frühwald; Norbert Graf; Andreas H Groll; Antonio Ruggiero; Georg Hempel; Joachim Boos
Journal:  BMC Pharmacol Toxicol       Date:  2020-05-28       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.